公开(公告)号：WO1998008848A1

公开(公告)日：1998-03-05

申请号：PCT/JP1997003023

申请日：1997-08-29

Applicant: KYOWA HAKKO KOGYO CO., LTD. ,  ONODA, Yasuo ,  NOMOTO, Yuji ,  OHNO, Tetsuji ,  YAMADA, Koji ,  ICHIMURA, Michio

Inventor： KYOWA HAKKO KOGYO CO., LTD.

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: Imidazoquinazoline derivatives represented by general formula (I) or pharmacologically acceptable salts thereof, which have potent and selective inhibitory effects on cyclic guanosine-3',5'-monophosphate (cGMP)-specific phosphodiesterase and are useful in, for example, treating or relieving cardiovascular diseases such as thrombosis, angina pectoris, hypertension, cardiac insufficiency and arteriosclerosis, asthma, etc. and treating sexual impotence. In said formula, R represents hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted bicycloalkyl, optionally substituted tricycloalkyl, etc.; R represents hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted bicyclaolkyl, optionally substituted tricycloalkyl, optionally substituted lower alkenyl, optionally substituted aralkyl, etc.; R represents hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted bicycloalkyl, optionally substituted tricycloalkyl, optionally substituted lower alkenyl, optionally substituted aralkyl, etc., or R and R may form together with N an optionally substituted heterocyclic group; and X represents O or S.

Abstract translation: 对通式（I）表示的咪唑并喹唑啉衍生物或其药理学上可接受的盐，对环鸟嘌呤-3'，5'-单磷酸（cGMP）特异性磷酸二酯酶具有有效和选择性的抑制作用，可用于例如治疗或缓解 心血管疾病如血栓形成，心绞痛，高血压，心功能不全和动脉硬化，哮喘等，并治疗性阳。。 在所述式中，R 1表示氢，任选取代的低级烷基，任选取代的环烷基，任选取代的双环烷基，任选取代的三环烷基等; R 2表示氢，任选取代的低级烷基，任选取代的环烷基，任选取代的双环烷基，任选取代的三环烷基，任选取代的低级烯基，任选取代的芳烷基等; R 3表示氢，任选取代的低级烷基，任选取代的环烷基，任选取代的双环烷基，任选取代的三环烷基，任选取代的低级链烯基，任选取代的芳烷基等，或R 2和R 3可与 N为任选取代的杂环基; X表示O或S.

公开(公告)号：WO1996026940A1

公开(公告)日：1996-09-06

申请号：PCT/JP1996000497

申请日：1996-03-01

Applicant: KYOWA HAKKO KOGYO CO., LTD. ,  ONODA, Yasuo ,  SASAKI, Shin-ichi ,  MACHII, Daisuke ,  TAKAI, Haruki ,  OHNO, Tetsuji ,  YAMADA, Koji ,  ICHIMURA, Michio ,  KASE, Hiroshi

Inventor： KYOWA HAKKO KOGYO CO., LTD.

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: Imidazoquinazoline derivatives represented by general formula (I) or pharmacologically acceptable salts thereof, wherein R represents hydrogen, optionally substituted lower alkyl, etc.; R and R are the same or different and each represents hydrogen, optionally substituted lower alkyl, optionally substituted aralkyl, optionally substituted aryl, etc., or R and R together form an optionally substituted nitrogenous heterocycle; R represents hydrogen or optionally substituted lower alkyl; X represents O or S; Y represents a single bond or O; and n is 0, 1, 2 or 3.

Abstract translation: 由通式（I）表示的咪唑并喹唑啉衍生物或其药理学上可接受的盐，其中R 1表示氢，任选取代的低级烷基等; R 2和R 3相同或不同，各自表示氢，任选取代的低级烷基，任选取代的芳烷基，任选取代的芳基等，或R 2和R 3一起形成任选取代的 含氮杂环 R 4表示氢或任选取代的低级烷基; X表示O或S; Y表示单键或O; n为0,1,2或3。

公开(公告)号：WO1995006648A1

公开(公告)日：1995-03-09

申请号：PCT/JP1994001456

申请日：1994-09-02

Applicant: KYOWA HAKKO KOGYO CO., LTD. ,  MACHII, Daisuke ,  MATSUNO, Kenji ,  KINOSHITA, Iwao ,  NOMOTO, Yuji ,  TAKAI, Haruki ,  OHNO, Tetuji ,  NAGASHIMA, Ken ,  ISHIKAWA, Tomoko ,  YAMADA, Koji ,  ICHIMURA, Michio ,  KASE, Kiroshi

Inventor： KYOWA HAKKO KOGYO CO., LTD.

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: An imidazoquinazoline derivative represented by formula (I) or a pharmacologically acceptable salt thereof, wherein R andR may be the same or different from each other and each represents hydrogen, lower alkyl, lower alkenyl, aryl, etc.; R represents hydrogen, lower alkyl, cycloalkyl, lower alkenyl, aryl, etc.; and X represents O or S. This compound has a potent and selective cCMP-specific PDE inhibitor activity and is useful for treating or mitigating cardiovascular diseases such as thrombosis, angina pectoris, hypertension and arteriosclerosis, asthma, and so forth.

Abstract translation: 由式（I）表示的咪唑并喹唑啉衍生物或其药理学上可接受的盐，其中R 1和R 2可以相同或不同，各自代表氢，低级烷基，低级烯基，芳基等; R 3表示氢，低级烷基，环烷基，低级烯基，芳基等; X表示O或S.该化合物具有有效和选择性的cCMP特异性PDE抑制剂活性，可用于治疗或缓解心血管疾病如血栓形成，心绞痛，高血压和动脉硬化，哮喘等。

公开(公告)号：WO1995000546A1

公开(公告)日：1995-01-05

申请号：PCT/JP1994001011

申请日：1994-06-23

Applicant: KYOWA HAKKO KOGYO CO., LTD. ,  SHIBATA, Kenji ,  SUZAWA, Toshiyuki ,  YAMASAKI, Motoo ,  TANAKA, Takeo ,  TSUKUDA, Eiji ,  YAMADA, Koji ,  OHNO, Tetsuji

Inventor： KYOWA HAKKO KOGYO CO., LTD.

IPC: C07K07/08

CPC classification number: C07K7/06 ,  A61K38/00 ,  C07K14/57536

Abstract: An endothelin-antagonizing peptide compound represented by general formula (I) and a pharmacologically acceptable salt thereof: R -R -R -R -R -R -R -R -R -R -R -R -Phe-R -R -R -R -R -Ile-R -Z wherein R is X -Gly, X (a), X -SCH2CO or hydrogen; R is Asn, Asp, Phe, Tyr, Ser or a single bond; R is Trp, Ile, Pro, Ala or a single bond; R is His, Lys, Gly, Trp, Ala or a single bond; R is Gly, Thr, Trp, Val or a single bond; R is Gly, Thr, Asn, Tyr, Asp or a single bond; R is Ala, Ser, Asn, Asp, Tyr, Phe or a single bond; R is Pro, Ala, Arg or a single bond; R is (b), (c) or a single bond; R is Trp or Ala; R is Val, Pro or a single bond; R is Tyr or a single bond; R is Ala, MeAla, Ser or Cys; R is His or Trp; R is Leu or Nva; R is Asp, Thr, Asn, Ser, Gly or Glu; R is Ile, Leu, Cha, Abu, Thi, Met, Tyr, MeLeu, MeIle, Phg or Nle; R is Trp, Phe or Tyr; and Z is hydroxy, lower alkoxy or amino.

Abstract translation: 由通式（I）表示的内皮素拮抗肽化合物及其药理学上可接受的盐：R 1 -R 2 -R 3 -R 4 -R 5 -R 6 - [R <7> -R <8> -R <9> -R <10> -R <11> -R <12> -Phe-R <14> -R <15> -R <16> -R <17 其中R 1为X 1 -Gly，X 3（a），X 2 -SCH 2 CO或氢; R 2是Asn，Asp，Phe，Tyr，Ser或单键; R 3是Trp，Ile，Pro，Ala或单键; R 4是His，Lys，Gly，Trp，Ala或单键; R 5是Gly，Thr，Trp，Val或单键; R 6是Gly，Thr，Asn，Tyr，Asp或单键; R 7是Ala，Ser，Asn，Asp，Tyr，Phe或单键; Pro，Ala，Arg或单键; R 9为（b），（c）或单键; R 10是Trp或Ala; R 11是Val，Pro或单键; R 12是Tyr或单键; R 14是Ala，MeAla，Ser或Cys; R 15是His或Trp; R 16是Leu或Nva; R 17是Asp，Thr，Asn，Ser，Gly或Glu; R 18是Ile，Leu，Cha，Abu，Thi，Met，Tyr，MeLeu，MeIle，Phg或Nle; R 20是Trp，Phe或Tyr; Z为羟基，低级烷氧基或氨基。

公开(公告)号：WO1988010262A1

公开(公告)日：1988-12-29

申请号：PCT/JP1987000416

申请日：1987-06-25

Applicant: BANYU PHARMACEUTICAL CO., LTD. ,  NAKAGAWA, Susumu ,  USHIJIMA, Ryosuke ,  NAKANO, Fumio ,  YAMADA, Koji ,  MANO, Eiichi

Inventor： BANYU PHARMACEUTICAL CO., LTD.

IPC: C07D501/46

CPC classification number: A61K31/545

Abstract: Stable crystalline hydrate of (6R, 7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-(1-carboxy-1-methylethoxyimino)-a cetamido]-3-(5,6-dihydroxy-2-methyl-2-isoindolinium)-methyl-3-cephem-4 -carboxylate which is useful as an agent for treating diseases caused by bacterial infection is disclosed.

Abstract translation: （6R，7R）-7 - [（Z）-2-（2-氨基噻唑-4-基）-2-（1-羧基-1-甲基乙氧基亚氨基）-α-鲸蜡基酰] -3-（5， 公开了可用作治疗由细菌感染引起的疾病的药剂的6-二羟基-2-甲基-2-异二氢吲哚鎓） - 甲基-3-头孢烯-4-羧酸酯。

公开(公告)号：WO2008152954A1

公开(公告)日：2008-12-18

申请号：PCT/JP2008/060250

申请日：2008-05-28

Applicant: CANON KABUSHIKI KAISHA ,  YAMADA, Koji

Inventor： YAMADA, Koji

IPC: G06F9/445

CPC classification number: G06F21/6218 ,  G06F8/61 ,  G06F2221/2141

Abstract: Commands such as installation operation and launch program commands need to be executed after appropriately switching between an administrator account and another account, for each command, when an installer constituting a program for readily performing installation operations collectively for a plurality of pieces of software or the like is launched. When an installer is launched in the present invention, process-to-process communication is secured between the processes of an administrator account and a user account, and an account to execute a command included in the installer is determined in the process of the administrator account. If the determination result indicates that the account to execute the command is the user account, the command is executed in the process of the user account rather than in the process of the administrator account.

Abstract translation: 在安装操作和启动程序命令之间的命令需要在管理员帐户与另一个帐户之间适当地切换时对于每个命令执行，当构成用于容易地对多个软件等进行安装操作的程序的安装程序时 被推出。 当在本发明中启动安装程序时，在管理员帐户和用户帐户的处理之间确保处理到进程的通信，并且在管理员帐户的过程中确定执行安装程序中包括的命令的帐户 。 如果确定结果指示执行该命令的帐户是用户帐户，则该命令在用户帐户的过程中执行，而不是在管理员帐户的过程中执行。

公开(公告)号：WO1997012872A1

公开(公告)日：1997-04-10

申请号：PCT/JP1996002880

申请日：1996-10-03

Applicant: EISAI CO., LTD. ,  MIYAMOTO, Mitsuaki ,  YOSHIUCHI, Tatsuya ,  SATO, Keizo ,  KAINO, Makoto ,  TAKASHIMA, Yoshihiro ,  MORIYA, Katsuhiro ,  SAKUMA, Yoshinori ,  YAMADA, Koji ,  HARADA, kOkichi ,  NISHIZAWA, Yukio ,  KOBAYASHI, Seiichi ,  OKITA, Makoto ,  KATAYAMA, Koichi

Inventor： EISAI CO., LTD.

IPC: C07D219/14

CPC classification number: C07D219/14

Abstract: Novel acridone compounds represented by general formula (I) or pharmacologically acceptable salts thereof efficacious in the prevention and treatment of diseases in which chemical transmitters (histamine, leukotriene, etc.) participate, typified by asthma, allergic rhinitis, atopic dermatitis, urticaria, hay fever, digestive tract allergy, food allergy, etc., wherein R , R , R , R , R and R are the same or different and each represents hydrogen, hydroxy, halogeno, lower alkyl, cycloalkyl, lower alkoxy, etc.; Y represents -(CH2)t-(B)m-(CH2)-Z [wherein m is 0 or 1; t and n represent each an integer of from 0 to 6; B represents lower alkylene, optionally substituted arylene, etc.; and Z represents cyano, optionally protected carboxy, acyl or -NR R (wherein R and R are the same or different and each represents hydrogen, lower alkyl, lower alkoxy, hydroxyalkyl, etc.)]; and D represents oxygen or sulfur.

Abstract translation: 由通式（I）表示的新型吖啶酮化合物或其药学上可接受的盐在预防和治疗化学发射器（组胺，白三烯等）参与的疾病中有效，以哮喘，过敏性鼻炎，特应性皮炎，荨麻疹，干草为代表 发热，消化道过敏，食物过敏等，其中R 1，R 2，R 3，R 4，R 5和R 6相同或不同，表示 氢，羟基，卤代，低级烷基，环烷基，低级烷氧基等; Y表示 - （CH 2）t - （B）m - （CH 2）-Z [其中m为0或1; t和n表示0〜6的整数。 B表示低级亚烷基，任选取代的亚芳基等; 和Z表示氰基，任意保护的羧基，酰基或-NR 7 R 8（其中R 7和R 8相同或不同，各自代表氢，低级烷基，低级烷氧基，羟基烷基等 。）]; D表示氧或硫。

公开(公告)号：WO1997012871A1

公开(公告)日：1997-04-10

申请号：PCT/JP1995002007

申请日：1995-10-02

Applicant: EISAI CO., LTD. ,  MIYAMOTO, Mitsuaki ,  YOSHIUCHI, Tatsuya ,  ABE, Shinya ,  TANAKA, Masayuki ,  MORIYA, Katsuhiro ,  KATAYAMA, Satoshi ,  YAMANAKA, Takashi ,  YAMADA, Koji

Inventor： EISAI CO., LTD.

IPC: C07D219/06

CPC classification number: C07D219/14

Abstract: An acridone derivative represented by general formula (I) and a pharmacologically acceptable salt thereof, efficacious in preventing or treating deseases wherein histamine, leucotriene and the like participate and allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, urticaria, hay fever, gastrointestinal allergy, and food allergy, wherein R to R represent each hydrogen, lower alkyl, etc.; and n represents an integer of 1 to 6.

Abstract translation: 由通式（I）表示的吖啶酮衍生物及其药理学上可接受的盐可有效预防或治疗组胺，白三烯等参与的过敏性疾病如哮喘，过敏性鼻炎，特应性皮炎，荨麻疹，花粉症，胃肠道 过敏和食物过敏，其中R 1至R 8表示每个氢，低级烷基等; n表示1〜6的整数。

公开(公告)号：WO2008152954A4

公开(公告)日：2009-04-23

申请号：PCT/JP2008060250

申请日：2008-05-28

Applicant: CANON KK ,  YAMADA KOJI

Inventor： YAMADA KOJI

IPC: G06F9/445

CPC classification number: G06F21/6218 ,  G06F8/61 ,  G06F2221/2141

Abstract: Commands such as installation operation and launch program commands need to be executed after appropriately switching between an administrator account and another account, for each command, when an installer constituting a program for readily performing installation operations collectively for a plurality of pieces of software or the like is launched. When an installer is launched in the present invention, process-to-process communication is secured between the processes of an administrator account and a user account, and an account to execute a command included in the installer is determined in the process of the administrator account. If the determination result indicates that the account to execute the command is the user account, the command is executed in the process of the user account rather than in the process of the administrator account.

Abstract translation: 在安装操作和启动程序命令之间的命令需要在管理员帐户与另一个帐户之间适当地切换时对于每个命令执行，当构成用于容易地对多个软件等进行安装操作的程序的安装程序时 被推出。 当在本发明中启动安装程序时，在管理员帐户和用户帐户的处理之间确保处理到进程的通信，并且在管理员帐户的过程中确定执行安装程序中包括的命令的帐户 。 如果确定结果指示执行该命令的帐户是用户帐户，则该命令在用户帐户的过程中执行，而不是在管理员帐户的过程中执行。

公开(公告)号：WO2007011809A1

公开(公告)日：2007-01-25

申请号：PCT/US2006/027543

申请日：2006-07-14

Applicant: MERCK & CO., INC. ,  BANYU PHARMACEUTICAL CO., LTD. ,  YAMAKAWA, Takeru ,  JONA, Hideki ,  NIIYAMA, Kenji ,  YAMADA, Koji ,  IINO, Tomoharu ,  OHKUBO, Mitsuru ,  IMAMURA, Hideaki ,  SHIBATA, Jun ,  KUSUNOKI, Jun ,  YANG, Lihu

Inventor： YAMAKAWA, Takeru ,  JONA, Hideki ,  NIIYAMA, Kenji ,  YAMADA, Koji ,  IINO, Tomoharu ,  OHKUBO, Mitsuru ,  IMAMURA, Hideaki ,  SHIBATA, Jun ,  KUSUNOKI, Jun ,  YANG, Lihu

IPC: C07D491/10 ,  C07D497/10 ,  A61K31/438 ,  A61P3/00 ,  A61P35/00 ,  A61P31/00

CPC classification number: C07D491/10 ,  C07D495/10

Abstract: The invention relates to a compound of a formula (I): , or a pharmaceutically acceptable salt or ester thereof, useful as a therapeutic agent for various ACC-related disorders.

Abstract translation: 本发明涉及可用作各种ACC相关疾病的治疗剂的式（I）的化合物或其药学上可接受的盐或酯。